AMGN.O
Latest Trade
252.17USDChange
-6.44(-2.49%)Volume
1,801,227Today's Range
-
259.4452 Week Range
-
264.97As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 258.60 |
---|---|
Open | 255.47 |
Volume | 1,801,227 |
3M AVG Volume | 50.53 |
Today's High | 259.44 |
Today's Low | 251.40 |
52 Week High | 264.97 |
52 Week Low | 177.05 |
Shares Out (MIL) | 582.17 |
Market Cap (MIL) | 150,548.80 |
Forward P/E | 16.00 |
Dividend (Yield %) | 2.72 |
EVOQ Therapeutics Announces A License And Collaboration Agreement With Amgen
Astrazeneca, Amgen Say Asthma Trial Did Not Meet Primary Endpoint
Amgen Says Source Phase 3 Trial For Tezepelumab Did Not Meet Primary Endpoint
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Industry
Biotechnology & Drugs
Contact Info
1 Amgen Center Dr
THOUSAND OAKS, CA
91320-1730
United States
+1.805.4471000
http://www.amgen.comExecutive Leadership
Robert A. Bradway
Chairman of the Board, President, Chief Executive Officer
Peter H. Griffith
Chief Financial Officer, Executive Vice President
Murdo Gordon
Executive Vice President of Global Commercial Operations
David M. Reese
Executive Vice President - Research and Development
Esteban Santos
Executive Vice President, Operations
Price To Earnings (TTM) | 20.85 |
---|---|
Price To Sales (TTM) | 6.03 |
Price To Book (MRQ) | 13.77 |
Price To Cash Flow (TTM) | 13.96 |
Total Debt To Equity (MRQ) | 312.87 |
LT Debt To Equity (MRQ) | 312.04 |
Return on Investment (TTM) | 14.21 |
Return on Equity (TTM) | 11.84 |
AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids, while keeping the respiratory condition in check in a late-stage trial.
Drugmakers AstraZeneca and Amgen said on Tuesday their experimental asthma drug tezepelumab failed to meet the main goal of reducing patients' dependence on steroids while keeping the condition in check in a late-stage trial.
Drugmakers Amgen Inc and AstraZeneca Plc said on Tuesday a pivotal trial found that their experimental medication tezepelumab significantly reduced asthma attacks for people with severe forms of the respiratory condition compared to a placebo.
Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla in a late-stage study.
Amgen Inc on Wednesday said third-quarter adjusted profit rose 17% due to stronger sales of drugs such as osteoporosis treatment Prolia and psoriasis medication Otezla, bucking challenges from lower drug prices and COVID-19.
Amgen Inc on Wednesday said its third-quarter adjusted profit rose 17% due to stronger sales of drugs including the osteoporosis treatment Prolia and recently-acquired psoriasis medication Otezla.
Eli Lilly and Co on Thursday partnered with Amgen Inc to increase the supply of its experimental COVID-19 antibody treatments, a day after one of Lilly's drugs was shown to reduce the need for hospitalization.
Eli Lilly and Co on Thursday entered into an agreement with Amgen Inc to increase the supply capacity of the drugmaker's experimental COVID-19 antibody treatments.
Amgen Inc said on Tuesday second-quarter revenue rose 6% as higher sales of newer drugs, including recently added psoriasis treatment Otezla, offset declining sales of older medicines which were due in some cases to people staying home to avoid exposure to the new coronavirus...
Amgen Inc on Tuesday reported second-quarter revenue rose 6% as higher sales of newer drugs, including recently-added psoriasis treatment Otezla, offset declining sales of older medicines.
Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for COVID-19, the respiratory illness caused by the new coronavirus.
Moderna Inc on Thursday named David Meline its chief financial officer, as the company develops a potential vaccine for the respiratory illness caused by the new coronavirus.
Amgen Inc on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.
Amgen Inc on Thursday reported better-than-expected first-quarter results on Thursday and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.
Amgen Inc on Thursday said its fourth-quarter sales fell 2% due to competition from lower-cost generic drugs and biosimilars, but share buybacks enabled the company to post a profit that topped Wall Street estimates.
Biotechnology giant Amgen Inc expects up to a quarter of its growth to come from Asia over the next decade, Chief Executive Officer Robert Bradway told Reuters.
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.
The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.
Abarca, a small Puerto Rico-based pharmacy benefits manager, said on Tuesday Amgen Inc had agreed to give its health insurer clients an additional discount on its blockbuster rheumatoid arthritis drug Enbrel, if patients discontinue taking it after three months.
Swiss drugmaker Novartis is betting on heart drug prospect inclisiran in a $9.7 billion takeover of The Medicines Co as it challenges cardiovascular medicines from Amgen Inc, Sanofi and Regeneron Pharmaceuticals.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.